Insulet announced its groundbreaking Omnipod 5 Automated Insulin Delivery System is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Street analysts say diabetes stocks âoverreactingâ to Lilly GLP-1 study results
- Diabetes stock selloff on Lilly Surmount-1 results overdone, says Citi
- Insulet opens new manufacturing facility in Malaysia
- ‘Frustrated’ JPMorgan remains buyer of Insulet after Q2 beat
- Insulet price target raised to $220 from $200 at Barclays